Tenenbein M
Pediatr Neurosci. 1985;12(3):161-4. doi: 10.1159/000120240.
The neuroleptic malignant syndrome (NMS) is an idiosyncratic reaction to neuroleptic medication not previously described in the pediatric literature. It is characterized by hyperthermia, extrapyramidal disorders, decreased level of consciousness and autonomic dysfunction. A 15-year-old boy with acute lymphoblastic leukemia developed the NMS after a brief exposure to chlorpromazine and promethazine. He responded favorably to the dopamine agonist bromocriptine. A review of the recent literature suggests bromocriptine as the most efficacious specific therapy. Management of the NMS includes immediate discontinuation of all neuroleptic agents, intense supportive care and prompt institution of bromocriptine therapy.
神经阻滞剂恶性综合征（NMS）是一种对神经阻滞剂药物的特异反应，儿科文献中此前未对其进行过描述。其特征为高热、锥体外系障碍、意识水平降低及自主神经功能障碍。一名15岁的急性淋巴细胞白血病男孩在短期接触氯丙嗪和异丙嗪后发生了NMS。他对多巴胺激动剂溴隐亭反应良好。近期文献综述表明溴隐亭是最有效的特异性治疗药物。NMS的处理包括立即停用所有神经阻滞剂药物、加强支持治疗并迅速开始溴隐亭治疗。
